Principal Investigator
Byron Lam
Enrollment Status
Open
Clinical Trial ID
Institutional Protocol #
20240647
Clinical Trial Summary
A Phase 1/2, First-in-Human, Open-label, Assessor-Masked, Randomized, Controlled,
Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of a
Subretinal Injection of SB-007 in Subjects with Stargardt Disease (STGD1) Caused by Bi-Allelic
Autosomal Recessive Mutations in the ATP Binding Cassette Subfamily A Member 4 (ABCA4) Gene
Phase
TBD
Funding Agency/Sponsor
Industry
Disease
Other